SlideShare a Scribd company logo
Myocardial Ischemia
Presented by
Priyanka Priyadrsani Nayak
Myocardial Ischemia
• Myocardial ischemia occurs when the blood
flow demands of the heart exceed the blood
supplied by the coronary arteries.
• The leading cause of myocardial
ischemia is:
a) atherosclerosis or
b) Coronary thrombosis.
pathophysiology of myocardial
ischemia:
Under conditions of rest, myocardial oxygen supply and
delivery of nutrients through the coronary arteries should
match the metabolic requirements of the heart. When the
metabolic needs of the heart increase, the coronary blood
flow must increase accordingly.
The myocardial oxygen balance is affected by several factors
that :
a) will increase the oxygen and nutrient demand of the
myocardium as: exercise, stress and cold.
b) will increase coronary blood flow as cardiac metabolites and
nitric oxide.
 With age and progressive occlusion of coronary arteries, smaller
collateral vessels may begin to carry a greater proportion of
blood and provide an alternate means of perfusion for an area
of myocardium. These collateral blood vessels may run parallel
to the larger coronary arteries and be connected to other small
coronary vessels by vascular connections called anastomoses.
 Development of collateral circulation may reduce or delay the
occurrence of symptoms from myocardial ischemia until the
blockage is very progressed.
 The presence of extensively developed collateral circulation
might also explain why many older individuals often survive
serious heart attacks when younger individuals, who have not
yet developed collateral circulation, often do not.
Manifestation of myocardial
ischemia:
• Angina pectoris
 It is the major symptom of myocardial ischemia.
 Angina pectoris most commonly presents as severe
pain the chest.
There are three types of Angina pectoris
1. Classic or stable angina
Pain is precipitated by increased workload on the heart. May be
caused by exercise, emotions, stress and cold exposure.
Symptoms may remain “stable” for a number of years or progress in
severity.
2. Unstable angina
Angina that occurs at rest.
Also referred to as “pre-infarct” angina since it is usually
associated with extensive blockage of coronary arteries. Coronary
blood flow does not meet the needs of the heart even at rest.
Requires intensive treatment and evaluation.
3. Variant angina (vasospastic angina, Prinzmetal’s angina)
Caused by vasospasm of the coronary arteries.
Usually associated with coronary artery disease but may result
from excess sympathetic activity.
Frequently occurs at night, at rest or during minimal exercise.
May be precipitated by stress, cold exposure or smoking.
Silent ischemia
is a particularly dangerous form
of myocardial ischemia as there
is a lack of clinical symptoms,
i.e., ischemia without angina.
Usually diagnosed by exercise
stress testing or Holter
monitoring.
Diagnosis of myocardial ischemia:
1. Electrocardiograph
2. Holter monitoring — 24 ambulatory electrocardiograph
3. Stress testing with electrocardiograph
4. Nuclear imaging
5. Cardiac catheterization
Rationale for treatment of myocardial
ischemia:
• Treatment of myocardial ischemia
and the resulting angina can
involve two strategies:
• 1. Increase coronary blood flow by
dilating coronary arteries.
• 2. Reduce cardiac workload by
reducing heart rate and/or force of
contraction
The treatment regimen may include :
1. nonpharmacologic treatment
2. pharmacologic therapies.
Nonpharmacologic treatment
Pacing of physical activity.
• Avoidance of stress (emotional, physiologic, cold).
• Reduction of risk factors for ischemic heart disease,
(hyperlipidemia, obesity, hypertension, diabetes,
smoking, etc.)
Pharmacologic treatment
Organic Nitrates
Mechanism of action:
• Dilate coronary arteries and increase myocardial blood flow.
• Dilate peripheral arteries and reduce afterload.
• Dilate peripheral veins and reduce preload.
Examples
Amyl nitrate, nitroglycerine, isosorbide dinitrite
Route of administration : Inhalation, sublingual, oral, transdermal, intravenous
Long-acting forms such as isosorbide dinitrite used for prophylaxis of angina
Short-acting forms such as sublingual nitroglycerin may be used during angina
attacks
Major adverse effects :include headache, hypotension. Tolerance may develop
rapidly.
β-Adrenergic blockers
Mechanism of action:
Block myocardial β-adrenergic receptors.
Reduce heart rate and cardiac output (reduced
myocardial workload and oxygen demand).
Examples of β-Adrenergic Receptor Antagonists :
May be selective β1 (atenolol), or
nonselective β1 and β2 blockers (propranolol)
Major adverse effects :
include bradycardia, reduced cardiac output,
pacemaker
depression and bronchoconstriction with
nonspecific drugs
Calcium channel blockers
• Mechanism of action:
• Block calcium channels in vascular smooth muscle.
• Dilate coronary arteries and increase myocardial blood flow.
• Dilate peripheral arteries and reduce afterload.
Examples: Dihydropyridines (nifedipine), verapamil, diltiazem
Dihydropyridines have greater specificity for relaxing vascular smooth muscle
Verapmail and diltiazem have greater effects on cardiac pacemaker tissues
Major adverse effects include headache, hypotension, reflex tachycardia; risk of
heart block of cardiac failure particularly with verapamil or diltiazem
Also used for hypertension and arrhythmia
Aspirin
• Prevent platelet aggregation.
• Use for prophylaxis of blood clots particularly
in unstable angina.
Surgical treatment
• Coronary angioplasty
• Uses a balloon catheter to open occluded blood vessels
• Usually performed under local anesthetic
• 5% mortality, high rate of vessel re-occlusion
• Use of metal “stents” in opened vessel reduces rate of
occlusion
Coronary artery bypass graft
• Revascularization procedure in which a blood vessel is taken from
elsewhere in the body and surgically sutured around a blocked
coronary artery
• May involve multiple (one to five) blood vessels
• Re-occlusion of transplanted vessel is possible
Myocardial Infarction
• Myocardial infarction or “heart attack” is an irreversible injury to and
eventual death of myocardial tissue that results from ischemia and
hypoxia.
• Myocardial infarction is the leading killer of both men and women in
the United States.
• Most heart attacks are the direct result of occlusion of a coronary
blood vessel by a lipid deposit. These lipid deposits may accumulate
to the point where they completely block a coronary vessel or, more
commonly, accumulated lipid plaques may break off from the
vascular endothelium and act as a thrombus that blocks a coronary
artery at a narrower point downstream. Prolonged vasospasm might
also precipitate a myocardial infarction in certain individuals.
Coronary Arteries for the heart
The two main coronary arteries supplying the
myocardium are:
1. the left coronary artery (which subdivides into the
left anterior descending and circumflex branches) and
2. the right coronary artery
• The left anterior descending artery supplies blood to
the bulk of the anterior left ventricular wall, while the
left circumflex artery provides blood to the left atrium
and the posterior and lateral walls of the left ventricle.
The right coronary artery provides blood mainly to the
right atria and right ventricles.
• Nearly 50% of all myocardial infarctions involve the left
anterior descending artery that supplies blood to the
main pumping mass of the left ventricle.
• The next most common site for myocardial infarction is
the right coronary artery, followed by the left
circumflex.
A myocardial infarction may be:
a) transmural, meaning it involves the full thickness
of the ventricular wall, or
b) subendocardial, in which the inner one third to
one half of the ventricular wall is involved.
Transmural infarcts tend to have a greater effect on
cardiac function and pumping ability since a greater
mass of ventricular muscle is involved.
Manifestations of myocardial
infarction
1. Severe chest pain and discomfort : Pressing or crushing
sensation often accompanied by nausea, vomiting, sweating
and weakness due to hypotension. A significant percentage of
myocardial infarctions are “silent” and have no symptoms.
2. Irreversible cellular injury: Generally occurs 20 to 30 minutes
after the onset of complete ischemia.
3. Release of myocardial enzymes such as creatine
phosphokinase (CPK) and lactate dehydrogenase (LDH) into
circulation from myocardial damaged cells.
4.Electrocardiogram changes : Inversion of T wave, ST
elevation, pronounced Q waves.
5.Inflammatory response from the injured myocardium :
Leukocyte infiltration, increased white blood cell
counts, fever.
6. Coagulative necrosis of the area of the myocardium
affected by the infarction.
7. Repair of damaged areas occurs by replacement with
scar tissue and not functional muscle tissue; therefore,
some alteration in function is inevitable
Complications of myocardial
infarction
Depending on the extent of the area involved in a myocardial
infarction, a number of complications might arise, including:
1. Rupture of weakened myocardial wall. Bleeding into pericardium
may cause cardiac tamponade and further impair cardiac pumping
function. This is most likely to occur with a transmural infarction.
Rupture of the septum between the ventricles might also occur if
the septal wall is involved in the infarction.
2. Formation of a thromboembolism from pooling of blood in the
ventricles.
3. Pericarditis : Inflammation due to pericardial friction rub. Often
occurs 1 to 2 days after the infarction.
4. Arrhythmia : Common as a result of hypoxia, acidosis and altered
electrical conduction through damaged and necrotic areas of the
myocardium. May be life-threatening and lead to fibrillation.
5. Reduced cardiac function : Typically presents with reduced
myocardial contractility, reduced wall compliance, decreased
stroke volume and increased left ventricular end diastolic
volume.
6. Congestive heart failure: may result if a large enough area of
the myocardium has been damaged such that the heart no
longer pumps effectively.
7. Cardiogenic shock : Marked hypotension that can result from
extensive damage to the left ventricle. The resulting
hypotension will trigger cardiovascular compensatory
mechanisms that will further tax the damaged myocardium
and exacerbate impaired function. Cardiogenic shock is
associated with a mortality rate of 80% or greater.
Compensatory mechanisms of
myocardial infarction
As a result of the hypotension and hemodynamic changes that accompany a
myocardial infarction, the cardiovascular system initiates a number of
reflex compensatory mechanisms designed to maintain cardiac output
and adequate tissue perfusion :
1.Catecholamine release : Increases heart rate, force of contraction and
peripheral resistance.
2. Sodium and water retention.
3. Activation of renin–angiotensin system leading to peripheral
vasoconstriction.
4. Ventricular hypertrophy.
Unfortunately, these compensatory changes may increase oxygen demand and
workload on the infarcted heart and worsen overall cardiac function.
Treatment for myocardial infarction
1. Oxygen : Used to maintain blood oxygenation as well as
tissue and cardiac O2 levels.
2. Aspirin : If administered when myocardial infarction is
detected, the antiplatelet properties of aspirin may reduce
the overall size of the infarction.
3. Thrombolytic therapy :If employed in the first 1 to 4 hours
following the onset of a myocardial infarction, these drugs
may dissolve clots in coronary blood vessels and re-
establish blood flow.
4. Vasodilator drugs : Intravenous nitroglycerin can increase
blood flow to the myocardium and reduce myocardial work.
5.β -Blockers : Blunt the effect of catecholamine release on the
myocardium, reduce heart rate and myocardial work.
6. Pain management : Sublingual nitroglycerin, morphine if
necessary
7. Antiarrhythmic drugs : To treat and prevent a number of
potentially life-threatening arrhythmias that might arise
following a myocardial infarction.
8. ACE inhibitors : the negative effects of vasoconstriction and
salt and water retention on the myocardium.
Thrombolytic Agents Used Clinically
a. Streptokinase : Derived from β -hemolytic streptococcus
bacteria; involved in the activation of plasmin
b. Anistreplase (APSAC) : Complex of human lys-plasminogen
and streptokinase; Administered as a prodrug
c. Alteplase (TPA): Recombinant tissue plasminogen activator
d. Urokinase : Endogenous human enzyme that converts
plasminogen to active plasmin
e. Routes of administration : Intravenous. for all of the above
f. Major unwanted effects : Internal bleeding,
gastrointestinal bleeding, stroke, allergic reactions
•Thank You

More Related Content

What's hot

Angina
AnginaAngina
Angina
samiya shaik
 
Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failureFuad Farooq
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.pptShama
 
Heart failure ppt
Heart failure pptHeart failure ppt
Heart failure ppt
THUSHARA MOHAN
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
salman habeeb
 
Cardiac action potential
Cardiac action potentialCardiac action potential
Cardiac action potential
Nikhil Vaishnav
 
Atrial septal defect
Atrial septal defectAtrial septal defect
Atrial septal defect
Dr. Maimuna Sayeed
 
dialated cardiomyopathies
dialated cardiomyopathiesdialated cardiomyopathies
dialated cardiomyopathies
Abhay Mange
 
Aneurysms
AneurysmsAneurysms
Arrhythmias
ArrhythmiasArrhythmias
Arrhythmias
Swatilekha Das
 
Heart block
Heart blockHeart block
Heart block
Chinna Chadayan
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases pptUma Binoy
 
Acute Coronary Syndrome - Overview
Acute Coronary Syndrome - OverviewAcute Coronary Syndrome - Overview
Acute Coronary Syndrome - Overview
Rahul Varshney
 
Cardiomyopathies
CardiomyopathiesCardiomyopathies
Cardiomyopathies
Sachin Adukia
 
ECG Changes in Myocardial Infarction
ECG Changes in Myocardial InfarctionECG Changes in Myocardial Infarction
ECG Changes in Myocardial Infarction
Adeboye Oluwajuyitan
 
LBBB
LBBBLBBB
LBBB
Aswin Rm
 
Arrythmia
ArrythmiaArrythmia
Arrythmia
aishuanju
 

What's hot (20)

Angina
AnginaAngina
Angina
 
Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failure
 
Ischemic Heart Disease
Ischemic Heart DiseaseIschemic Heart Disease
Ischemic Heart Disease
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.ppt
 
Heart failure ppt
Heart failure pptHeart failure ppt
Heart failure ppt
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
Ischemic Heart Disease
Ischemic Heart DiseaseIschemic Heart Disease
Ischemic Heart Disease
 
Cardiac action potential
Cardiac action potentialCardiac action potential
Cardiac action potential
 
Atrial septal defect
Atrial septal defectAtrial septal defect
Atrial septal defect
 
dialated cardiomyopathies
dialated cardiomyopathiesdialated cardiomyopathies
dialated cardiomyopathies
 
Aneurysms
AneurysmsAneurysms
Aneurysms
 
Arrhythmias
ArrhythmiasArrhythmias
Arrhythmias
 
Heart block
Heart blockHeart block
Heart block
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases ppt
 
Ecg & arrhythmias
Ecg & arrhythmiasEcg & arrhythmias
Ecg & arrhythmias
 
Acute Coronary Syndrome - Overview
Acute Coronary Syndrome - OverviewAcute Coronary Syndrome - Overview
Acute Coronary Syndrome - Overview
 
Cardiomyopathies
CardiomyopathiesCardiomyopathies
Cardiomyopathies
 
ECG Changes in Myocardial Infarction
ECG Changes in Myocardial InfarctionECG Changes in Myocardial Infarction
ECG Changes in Myocardial Infarction
 
LBBB
LBBBLBBB
LBBB
 
Arrythmia
ArrythmiaArrythmia
Arrythmia
 

Similar to Myocardial ischemia

Ischemic Heart Diseases
Ischemic Heart DiseasesIschemic Heart Diseases
Ischemic Heart Diseases
Eneutron
 
ISCHEMIC HEART DISEASE.pptx
ISCHEMIC HEART DISEASE.pptxISCHEMIC HEART DISEASE.pptx
ISCHEMIC HEART DISEASE.pptx
mariaidrees3
 
2. ISCHEMIC HEART DISEASE.pptx
2. ISCHEMIC HEART DISEASE.pptx2. ISCHEMIC HEART DISEASE.pptx
2. ISCHEMIC HEART DISEASE.pptx
mariaidrees3
 
Ischaemic heart disease
Ischaemic heart diseaseIschaemic heart disease
Ischaemic heart disease
shruthi manjunath
 
Pathophysiology and management of shock
 Pathophysiology and management of shock Pathophysiology and management of shock
Pathophysiology and management of shock
Soujanya Pharm.D
 
Samir rafla principles of cardiology pages 62 86 --
Samir rafla principles of cardiology pages 62 86 --Samir rafla principles of cardiology pages 62 86 --
Samir rafla principles of cardiology pages 62 86 --
Alexandria University, Egypt
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
Aamir Sharif
 
Internal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdf
Internal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdfInternal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdf
Internal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdf
Sani42793
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
Aamir Sharif
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
Aamir Sharif
 
Anti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & SymptomsAnti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Chetan Prakash
 
lecture 3 Cardiac alteration
lecture 3 Cardiac alteration lecture 3 Cardiac alteration
lecture 3 Cardiac alteration
ArabAlkhadam
 
Ischemic Heart Disease.pptx
Ischemic Heart Disease.pptxIschemic Heart Disease.pptx
Ischemic Heart Disease.pptx
AmalRashid10
 
Heart failure.ppt
Heart failure.pptHeart failure.ppt
Heart failure.ppt
fgcpkinaeehilrjwvw
 
hypertension
hypertensionhypertension
hypertension
Lissy Lecturer
 
MYOCARDIAL INFARACTION.pptx
MYOCARDIAL INFARACTION.pptxMYOCARDIAL INFARACTION.pptx
MYOCARDIAL INFARACTION.pptx
DINESH SINGH
 

Similar to Myocardial ischemia (20)

Ischemic Heart Diseases
Ischemic Heart DiseasesIschemic Heart Diseases
Ischemic Heart Diseases
 
Samir rafla principles of cardiology pages 62 86
Samir rafla principles of cardiology pages 62 86Samir rafla principles of cardiology pages 62 86
Samir rafla principles of cardiology pages 62 86
 
ISCHEMIC HEART DISEASE.pptx
ISCHEMIC HEART DISEASE.pptxISCHEMIC HEART DISEASE.pptx
ISCHEMIC HEART DISEASE.pptx
 
2. ISCHEMIC HEART DISEASE.pptx
2. ISCHEMIC HEART DISEASE.pptx2. ISCHEMIC HEART DISEASE.pptx
2. ISCHEMIC HEART DISEASE.pptx
 
Ischaemic heart disease
Ischaemic heart diseaseIschaemic heart disease
Ischaemic heart disease
 
Pathophysiology and management of shock
 Pathophysiology and management of shock Pathophysiology and management of shock
Pathophysiology and management of shock
 
Samir rafla principles of cardiology pages 62 86 --
Samir rafla principles of cardiology pages 62 86 --Samir rafla principles of cardiology pages 62 86 --
Samir rafla principles of cardiology pages 62 86 --
 
shock.pptx
shock.pptxshock.pptx
shock.pptx
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
 
Internal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdf
Internal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdfInternal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdf
Internal Medicine Lecture 4 Chronic forms of ischemic heart disease.pdf
 
Ischemic heart diseases 2
Ischemic heart diseases 2Ischemic heart diseases 2
Ischemic heart diseases 2
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
 
Afshan ali myocardial infarction
Afshan ali myocardial infarctionAfshan ali myocardial infarction
Afshan ali myocardial infarction
 
Anti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & SymptomsAnti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
 
lecture 3 Cardiac alteration
lecture 3 Cardiac alteration lecture 3 Cardiac alteration
lecture 3 Cardiac alteration
 
Ischemic Heart Disease.pptx
Ischemic Heart Disease.pptxIschemic Heart Disease.pptx
Ischemic Heart Disease.pptx
 
Heart failure.ppt
Heart failure.pptHeart failure.ppt
Heart failure.ppt
 
Angina Pectoris, e-Medicine Article
Angina Pectoris, e-Medicine ArticleAngina Pectoris, e-Medicine Article
Angina Pectoris, e-Medicine Article
 
hypertension
hypertensionhypertension
hypertension
 
MYOCARDIAL INFARACTION.pptx
MYOCARDIAL INFARACTION.pptxMYOCARDIAL INFARACTION.pptx
MYOCARDIAL INFARACTION.pptx
 

More from priyanka.p. Nayak

Cell signaling
Cell signaling Cell signaling
Cell signaling
priyanka.p. Nayak
 
Antifilariasis
AntifilariasisAntifilariasis
Antifilariasis
priyanka.p. Nayak
 
Study of advanced drugs from natural sources of antidiabetic agents
Study of advanced drugs from natural sources of antidiabetic agentsStudy of advanced drugs from natural sources of antidiabetic agents
Study of advanced drugs from natural sources of antidiabetic agents
priyanka.p. Nayak
 
Usfda ppn
Usfda ppnUsfda ppn
Bioassay of measles vaccine
Bioassay of measles vaccineBioassay of measles vaccine
Bioassay of measles vaccine
priyanka.p. Nayak
 
Diuretics...
Diuretics...Diuretics...
Diuretics...
priyanka.p. Nayak
 
Gpat preparation 2018
Gpat preparation 2018Gpat preparation 2018
Gpat preparation 2018
priyanka.p. Nayak
 
Pharmacy carrier plan
Pharmacy carrier planPharmacy carrier plan
Pharmacy carrier plan
priyanka.p. Nayak
 
Principles of toxicology
Principles of toxicologyPrinciples of toxicology
Principles of toxicology
priyanka.p. Nayak
 
Reverse pharmacognosy
Reverse pharmacognosyReverse pharmacognosy
Reverse pharmacognosy
priyanka.p. Nayak
 
Chf ppn
Chf ppnChf ppn

More from priyanka.p. Nayak (11)

Cell signaling
Cell signaling Cell signaling
Cell signaling
 
Antifilariasis
AntifilariasisAntifilariasis
Antifilariasis
 
Study of advanced drugs from natural sources of antidiabetic agents
Study of advanced drugs from natural sources of antidiabetic agentsStudy of advanced drugs from natural sources of antidiabetic agents
Study of advanced drugs from natural sources of antidiabetic agents
 
Usfda ppn
Usfda ppnUsfda ppn
Usfda ppn
 
Bioassay of measles vaccine
Bioassay of measles vaccineBioassay of measles vaccine
Bioassay of measles vaccine
 
Diuretics...
Diuretics...Diuretics...
Diuretics...
 
Gpat preparation 2018
Gpat preparation 2018Gpat preparation 2018
Gpat preparation 2018
 
Pharmacy carrier plan
Pharmacy carrier planPharmacy carrier plan
Pharmacy carrier plan
 
Principles of toxicology
Principles of toxicologyPrinciples of toxicology
Principles of toxicology
 
Reverse pharmacognosy
Reverse pharmacognosyReverse pharmacognosy
Reverse pharmacognosy
 
Chf ppn
Chf ppnChf ppn
Chf ppn
 

Recently uploaded

erythropoiesis-I_mechanism& clinical significance.pptx
erythropoiesis-I_mechanism& clinical significance.pptxerythropoiesis-I_mechanism& clinical significance.pptx
erythropoiesis-I_mechanism& clinical significance.pptx
muralinath2
 
Lateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensiveLateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensive
silvermistyshot
 
role of pramana in research.pptx in science
role of pramana in research.pptx in sciencerole of pramana in research.pptx in science
role of pramana in research.pptx in science
sonaliswain16
 
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
University of Maribor
 
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...
Wasswaderrick3
 
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
Sérgio Sacani
 
Seminar of U.V. Spectroscopy by SAMIR PANDA
 Seminar of U.V. Spectroscopy by SAMIR PANDA Seminar of U.V. Spectroscopy by SAMIR PANDA
Seminar of U.V. Spectroscopy by SAMIR PANDA
SAMIR PANDA
 
BLOOD AND BLOOD COMPONENT- introduction to blood physiology
BLOOD AND BLOOD COMPONENT- introduction to blood physiologyBLOOD AND BLOOD COMPONENT- introduction to blood physiology
BLOOD AND BLOOD COMPONENT- introduction to blood physiology
NoelManyise1
 
Toxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and ArsenicToxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and Arsenic
sanjana502982
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
Richard Gill
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
Lokesh Patil
 
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
Ana Luísa Pinho
 
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdfDMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
fafyfskhan251kmf
 
bordetella pertussis.................................ppt
bordetella pertussis.................................pptbordetella pertussis.................................ppt
bordetella pertussis.................................ppt
kejapriya1
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
Areesha Ahmad
 
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
Scintica Instrumentation
 
general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
IqrimaNabilatulhusni
 
GBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture MediaGBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture Media
Areesha Ahmad
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Sérgio Sacani
 
Leaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdfLeaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdf
RenuJangid3
 

Recently uploaded (20)

erythropoiesis-I_mechanism& clinical significance.pptx
erythropoiesis-I_mechanism& clinical significance.pptxerythropoiesis-I_mechanism& clinical significance.pptx
erythropoiesis-I_mechanism& clinical significance.pptx
 
Lateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensiveLateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensive
 
role of pramana in research.pptx in science
role of pramana in research.pptx in sciencerole of pramana in research.pptx in science
role of pramana in research.pptx in science
 
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
 
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...
 
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
 
Seminar of U.V. Spectroscopy by SAMIR PANDA
 Seminar of U.V. Spectroscopy by SAMIR PANDA Seminar of U.V. Spectroscopy by SAMIR PANDA
Seminar of U.V. Spectroscopy by SAMIR PANDA
 
BLOOD AND BLOOD COMPONENT- introduction to blood physiology
BLOOD AND BLOOD COMPONENT- introduction to blood physiologyBLOOD AND BLOOD COMPONENT- introduction to blood physiology
BLOOD AND BLOOD COMPONENT- introduction to blood physiology
 
Toxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and ArsenicToxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and Arsenic
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
 
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
 
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdfDMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
 
bordetella pertussis.................................ppt
bordetella pertussis.................................pptbordetella pertussis.................................ppt
bordetella pertussis.................................ppt
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
 
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...
 
general properties of oerganologametal.ppt
general properties of oerganologametal.pptgeneral properties of oerganologametal.ppt
general properties of oerganologametal.ppt
 
GBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture MediaGBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture Media
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
 
Leaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdfLeaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdf
 

Myocardial ischemia

  • 2. Myocardial Ischemia • Myocardial ischemia occurs when the blood flow demands of the heart exceed the blood supplied by the coronary arteries. • The leading cause of myocardial ischemia is: a) atherosclerosis or b) Coronary thrombosis.
  • 3. pathophysiology of myocardial ischemia: Under conditions of rest, myocardial oxygen supply and delivery of nutrients through the coronary arteries should match the metabolic requirements of the heart. When the metabolic needs of the heart increase, the coronary blood flow must increase accordingly. The myocardial oxygen balance is affected by several factors that : a) will increase the oxygen and nutrient demand of the myocardium as: exercise, stress and cold. b) will increase coronary blood flow as cardiac metabolites and nitric oxide.
  • 4.  With age and progressive occlusion of coronary arteries, smaller collateral vessels may begin to carry a greater proportion of blood and provide an alternate means of perfusion for an area of myocardium. These collateral blood vessels may run parallel to the larger coronary arteries and be connected to other small coronary vessels by vascular connections called anastomoses.  Development of collateral circulation may reduce or delay the occurrence of symptoms from myocardial ischemia until the blockage is very progressed.  The presence of extensively developed collateral circulation might also explain why many older individuals often survive serious heart attacks when younger individuals, who have not yet developed collateral circulation, often do not.
  • 5. Manifestation of myocardial ischemia: • Angina pectoris  It is the major symptom of myocardial ischemia.  Angina pectoris most commonly presents as severe pain the chest. There are three types of Angina pectoris 1. Classic or stable angina Pain is precipitated by increased workload on the heart. May be caused by exercise, emotions, stress and cold exposure. Symptoms may remain “stable” for a number of years or progress in severity.
  • 6. 2. Unstable angina Angina that occurs at rest. Also referred to as “pre-infarct” angina since it is usually associated with extensive blockage of coronary arteries. Coronary blood flow does not meet the needs of the heart even at rest. Requires intensive treatment and evaluation. 3. Variant angina (vasospastic angina, Prinzmetal’s angina) Caused by vasospasm of the coronary arteries. Usually associated with coronary artery disease but may result from excess sympathetic activity. Frequently occurs at night, at rest or during minimal exercise. May be precipitated by stress, cold exposure or smoking.
  • 7. Silent ischemia is a particularly dangerous form of myocardial ischemia as there is a lack of clinical symptoms, i.e., ischemia without angina. Usually diagnosed by exercise stress testing or Holter monitoring.
  • 8. Diagnosis of myocardial ischemia: 1. Electrocardiograph 2. Holter monitoring — 24 ambulatory electrocardiograph 3. Stress testing with electrocardiograph 4. Nuclear imaging 5. Cardiac catheterization
  • 9. Rationale for treatment of myocardial ischemia: • Treatment of myocardial ischemia and the resulting angina can involve two strategies: • 1. Increase coronary blood flow by dilating coronary arteries. • 2. Reduce cardiac workload by reducing heart rate and/or force of contraction
  • 10. The treatment regimen may include : 1. nonpharmacologic treatment 2. pharmacologic therapies. Nonpharmacologic treatment Pacing of physical activity. • Avoidance of stress (emotional, physiologic, cold). • Reduction of risk factors for ischemic heart disease, (hyperlipidemia, obesity, hypertension, diabetes, smoking, etc.)
  • 11. Pharmacologic treatment Organic Nitrates Mechanism of action: • Dilate coronary arteries and increase myocardial blood flow. • Dilate peripheral arteries and reduce afterload. • Dilate peripheral veins and reduce preload. Examples Amyl nitrate, nitroglycerine, isosorbide dinitrite Route of administration : Inhalation, sublingual, oral, transdermal, intravenous Long-acting forms such as isosorbide dinitrite used for prophylaxis of angina Short-acting forms such as sublingual nitroglycerin may be used during angina attacks Major adverse effects :include headache, hypotension. Tolerance may develop rapidly.
  • 12. β-Adrenergic blockers Mechanism of action: Block myocardial β-adrenergic receptors. Reduce heart rate and cardiac output (reduced myocardial workload and oxygen demand). Examples of β-Adrenergic Receptor Antagonists : May be selective β1 (atenolol), or nonselective β1 and β2 blockers (propranolol) Major adverse effects : include bradycardia, reduced cardiac output, pacemaker depression and bronchoconstriction with nonspecific drugs
  • 13. Calcium channel blockers • Mechanism of action: • Block calcium channels in vascular smooth muscle. • Dilate coronary arteries and increase myocardial blood flow. • Dilate peripheral arteries and reduce afterload. Examples: Dihydropyridines (nifedipine), verapamil, diltiazem Dihydropyridines have greater specificity for relaxing vascular smooth muscle Verapmail and diltiazem have greater effects on cardiac pacemaker tissues Major adverse effects include headache, hypotension, reflex tachycardia; risk of heart block of cardiac failure particularly with verapamil or diltiazem Also used for hypertension and arrhythmia
  • 14. Aspirin • Prevent platelet aggregation. • Use for prophylaxis of blood clots particularly in unstable angina.
  • 15. Surgical treatment • Coronary angioplasty • Uses a balloon catheter to open occluded blood vessels • Usually performed under local anesthetic • 5% mortality, high rate of vessel re-occlusion • Use of metal “stents” in opened vessel reduces rate of occlusion Coronary artery bypass graft • Revascularization procedure in which a blood vessel is taken from elsewhere in the body and surgically sutured around a blocked coronary artery • May involve multiple (one to five) blood vessels • Re-occlusion of transplanted vessel is possible
  • 16. Myocardial Infarction • Myocardial infarction or “heart attack” is an irreversible injury to and eventual death of myocardial tissue that results from ischemia and hypoxia. • Myocardial infarction is the leading killer of both men and women in the United States. • Most heart attacks are the direct result of occlusion of a coronary blood vessel by a lipid deposit. These lipid deposits may accumulate to the point where they completely block a coronary vessel or, more commonly, accumulated lipid plaques may break off from the vascular endothelium and act as a thrombus that blocks a coronary artery at a narrower point downstream. Prolonged vasospasm might also precipitate a myocardial infarction in certain individuals.
  • 17. Coronary Arteries for the heart The two main coronary arteries supplying the myocardium are: 1. the left coronary artery (which subdivides into the left anterior descending and circumflex branches) and 2. the right coronary artery
  • 18. • The left anterior descending artery supplies blood to the bulk of the anterior left ventricular wall, while the left circumflex artery provides blood to the left atrium and the posterior and lateral walls of the left ventricle. The right coronary artery provides blood mainly to the right atria and right ventricles. • Nearly 50% of all myocardial infarctions involve the left anterior descending artery that supplies blood to the main pumping mass of the left ventricle. • The next most common site for myocardial infarction is the right coronary artery, followed by the left circumflex.
  • 19. A myocardial infarction may be: a) transmural, meaning it involves the full thickness of the ventricular wall, or b) subendocardial, in which the inner one third to one half of the ventricular wall is involved. Transmural infarcts tend to have a greater effect on cardiac function and pumping ability since a greater mass of ventricular muscle is involved.
  • 20. Manifestations of myocardial infarction 1. Severe chest pain and discomfort : Pressing or crushing sensation often accompanied by nausea, vomiting, sweating and weakness due to hypotension. A significant percentage of myocardial infarctions are “silent” and have no symptoms. 2. Irreversible cellular injury: Generally occurs 20 to 30 minutes after the onset of complete ischemia. 3. Release of myocardial enzymes such as creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) into circulation from myocardial damaged cells.
  • 21. 4.Electrocardiogram changes : Inversion of T wave, ST elevation, pronounced Q waves. 5.Inflammatory response from the injured myocardium : Leukocyte infiltration, increased white blood cell counts, fever. 6. Coagulative necrosis of the area of the myocardium affected by the infarction. 7. Repair of damaged areas occurs by replacement with scar tissue and not functional muscle tissue; therefore, some alteration in function is inevitable
  • 22. Complications of myocardial infarction Depending on the extent of the area involved in a myocardial infarction, a number of complications might arise, including: 1. Rupture of weakened myocardial wall. Bleeding into pericardium may cause cardiac tamponade and further impair cardiac pumping function. This is most likely to occur with a transmural infarction. Rupture of the septum between the ventricles might also occur if the septal wall is involved in the infarction. 2. Formation of a thromboembolism from pooling of blood in the ventricles. 3. Pericarditis : Inflammation due to pericardial friction rub. Often occurs 1 to 2 days after the infarction. 4. Arrhythmia : Common as a result of hypoxia, acidosis and altered electrical conduction through damaged and necrotic areas of the myocardium. May be life-threatening and lead to fibrillation.
  • 23. 5. Reduced cardiac function : Typically presents with reduced myocardial contractility, reduced wall compliance, decreased stroke volume and increased left ventricular end diastolic volume. 6. Congestive heart failure: may result if a large enough area of the myocardium has been damaged such that the heart no longer pumps effectively. 7. Cardiogenic shock : Marked hypotension that can result from extensive damage to the left ventricle. The resulting hypotension will trigger cardiovascular compensatory mechanisms that will further tax the damaged myocardium and exacerbate impaired function. Cardiogenic shock is associated with a mortality rate of 80% or greater.
  • 24. Compensatory mechanisms of myocardial infarction As a result of the hypotension and hemodynamic changes that accompany a myocardial infarction, the cardiovascular system initiates a number of reflex compensatory mechanisms designed to maintain cardiac output and adequate tissue perfusion : 1.Catecholamine release : Increases heart rate, force of contraction and peripheral resistance. 2. Sodium and water retention. 3. Activation of renin–angiotensin system leading to peripheral vasoconstriction. 4. Ventricular hypertrophy. Unfortunately, these compensatory changes may increase oxygen demand and workload on the infarcted heart and worsen overall cardiac function.
  • 25. Treatment for myocardial infarction 1. Oxygen : Used to maintain blood oxygenation as well as tissue and cardiac O2 levels. 2. Aspirin : If administered when myocardial infarction is detected, the antiplatelet properties of aspirin may reduce the overall size of the infarction. 3. Thrombolytic therapy :If employed in the first 1 to 4 hours following the onset of a myocardial infarction, these drugs may dissolve clots in coronary blood vessels and re- establish blood flow. 4. Vasodilator drugs : Intravenous nitroglycerin can increase blood flow to the myocardium and reduce myocardial work.
  • 26. 5.β -Blockers : Blunt the effect of catecholamine release on the myocardium, reduce heart rate and myocardial work. 6. Pain management : Sublingual nitroglycerin, morphine if necessary 7. Antiarrhythmic drugs : To treat and prevent a number of potentially life-threatening arrhythmias that might arise following a myocardial infarction. 8. ACE inhibitors : the negative effects of vasoconstriction and salt and water retention on the myocardium.
  • 27. Thrombolytic Agents Used Clinically a. Streptokinase : Derived from β -hemolytic streptococcus bacteria; involved in the activation of plasmin b. Anistreplase (APSAC) : Complex of human lys-plasminogen and streptokinase; Administered as a prodrug c. Alteplase (TPA): Recombinant tissue plasminogen activator d. Urokinase : Endogenous human enzyme that converts plasminogen to active plasmin e. Routes of administration : Intravenous. for all of the above f. Major unwanted effects : Internal bleeding, gastrointestinal bleeding, stroke, allergic reactions